CL
KALV

CSS LLC’s KalVista Pharmaceuticals KALV Stock Holding History

CSS LLC’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-47,300
Closed -$320K – 814
2022
Q4 		$320K Buy
47,300
+19,200
+68% +$103K 0.02% 508
2022
Q3 		$408K Hold
28,100
– – 0.02% 574
2022
Q2 		$277K Buy
28,100
+26,900
+2,242% +$297K 0.01% 730
2022
Q1 		$18K Sell
1,200
-11,200
-90% -$161K ﹤0.01% 1075
2021
Q4 		$164K Buy
+12,400
New +$197K 0.01% 938
2021
Q3 		– Sell
-21,500
Closed -$515K – 1237
2021
Q2 		$515K Sell
21,500
-10,900
-34% -$285K 0.02% 619
2021
Q1 		$833K Buy
32,400
+25,400
+363% +$667K 0.03% 434
2020
Q4 		$133K Buy
+7,000
New +$120K 0.01% 681

Other funds holding KALV

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

CSS LLC's KALV Position: Q1 2023 in Review

CSS LLC sold out of KalVista Pharmaceuticals (KALV) in Q1 2023, closing a stake of 10,056 shares — an estimated $68K sold.

CSS LLC first reported a position in KALV in Q4 2020 and held it in 9 quarters. The position peaked at $1.03M in Q1 2021. 88 funds tracked by Wall St. Rank hold KALV as of Q1 2023.

  • CSS LLC reported no remaining KalVista Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • CSS LLC sold 10,056 KalVista Pharmaceuticals shares in Q1 2023, an estimated $68K.
  • CSS LLC first reported a position in KalVista Pharmaceuticals in Q4 2020 and held it in 9 quarters.
  • CSS LLC's KalVista Pharmaceuticals position peaked at $1.03M in Q1 2021.
  • 88 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2023.

Based on CSS LLC's 13F filing for Q1 2023, filed 15 May 2023.